menu
    • menu
    [{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chinese SLE Treatment And Research Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chinese SLE Treatment And Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Windgap Medical","sponsor":"Taiwania Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Series B Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Windgap Medical","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Windgap Medical \/ Taiwania Capital","highestDevelopmentStatusID":"1","companyTruncated":"Windgap Medical \/ Taiwania Capital"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"Verdure Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Illinois, Chicago \/ Verdure Sciences","highestDevelopmentStatusID":"1","companyTruncated":"University of Illinois, Chicago \/ Verdure Sciences"},{"orgOrder":0,"company":"Epiceutical Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Immunology","graph2":"Undisclosed","graph3":"Epiceutical Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epiceutical Labs \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Epiceutical Labs \/ Undisclosed"},{"orgOrder":0,"company":"Medinutra LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Immunology","graph2":"Undisclosed","graph3":"Medinutra LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medinutra LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Medinutra LLC \/ Undisclosed"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HavaH Therapeutics","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Hormone","year":"2021","type":"Licensing Agreement","leadProduct":"Testosterone","moa":"||Androgen Receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"HavaH Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"HavaH Therapeutics \/ Clarus Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"HavaH Therapeutics \/ Clarus Therapeutics"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Diosmin","moa":"Aryl hydrocarbon receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primus Pharmaceutical \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Primus Pharmaceutical \/ KGK Science"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Immunology","graph2":"Undisclosed","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Human Drug Research \/ Maruho","highestDevelopmentStatusID":"1","companyTruncated":"Centre for Human Drug Research \/ Maruho"},{"orgOrder":0,"company":"Laval University","sponsor":"Ministry of Agriculture, Fisheries and Food, Quebec | Ministry of economic development, innovation and export trade, Quebec | Diana Food, Symrise | Atrium Innovations | NutriAgaves, Mexico | Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Cranberry","moa":"Bacterial adhesion","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laval University \/ Ministry of Agriculture, Fisheries and Food, Quebec | Ministry of economic development, innovation and export trade, Quebec | Diana Food, Symrise | Atrium Innovations | NutriAgaves, Mexico | Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Laval University \/ Ministry of Agriculture, Fisheries and Food, Quebec | Ministry of economic development, innovation and export trade, Quebec | Diana Food, Symrise | Atrium Innovations | NutriAgaves, Mexico | Nestle Health Sciences SA"},{"orgOrder":0,"company":"NuLiv Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AstraGin","moa":"Bacterial gut","graph1":"Immunology","graph2":"Undisclosed","graph3":"NuLiv Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NuLiv Science \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NuLiv Science \/ Undisclosed"},{"orgOrder":0,"company":"Clalit","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Immunology","graph2":"Undisclosed","graph3":"Clalit","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clalit \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Clalit \/ Undisclosed"},{"orgOrder":0,"company":"Saskatchewan Health Authority \u2013 Regina Area","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Immunology","graph2":"Undisclosed","graph3":"Saskatchewan Health Authority \u2013 Regina Area","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saskatchewan Health Authority \u2013 Regina Area \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Saskatchewan Health Authority \u2013 Regina Area \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"VT-109","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Undisclosed","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Vera Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Stanford University \/ Vera Therapeutics"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tongji Hospital \/ IASO Bio","highestDevelopmentStatusID":"1","companyTruncated":"Tongji Hospital \/ IASO Bio"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Forest Laboratories | Lahey Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Forest Laboratories | Lahey Clinic","highestDevelopmentStatusID":"1","companyTruncated":"Brigham and Women's Hospital \/ Forest Laboratories | Lahey Clinic"},{"orgOrder":0,"company":"Rabin Medical Center","sponsor":"Leumit Health Services","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Undisclosed","graph3":"Rabin Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rabin Medical Center \/ Leumit Health Services","highestDevelopmentStatusID":"1","companyTruncated":"Rabin Medical Center \/ Leumit Health Services"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Institute for Clinical and Experimental Medicine","sponsor":"Charite University, Berlin, Germany | Miltenyi Biomedicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CZECH REPUBLIC","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Immunology","graph2":"Undisclosed","graph3":"Institute for Clinical and Experimental Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute for Clinical and Experimental Medicine \/ Charite University, Berlin, Germany | Miltenyi Biomedicine","highestDevelopmentStatusID":"1","companyTruncated":"Institute for Clinical and Experimental Medicine \/ Charite University, Berlin, Germany | Miltenyi Biomedicine"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"NextEvo Inc.","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"NextEvo Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NextEvo Inc. \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"1","companyTruncated":"NextEvo Inc. \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"The Valens Company","sponsor":"PMI Mexico","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"The Valens Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil","sponsorNew":"The Valens Company \/ PMI Mexico","highestDevelopmentStatusID":"1","companyTruncated":"The Valens Company \/ PMI Mexico"},{"orgOrder":0,"company":"Raphael Pharma","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Raphael Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raphael Pharma \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Raphael Pharma \/ Citruslabs"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD7 CAR-T Cell","moa":"CD7","graph1":"Immunology","graph2":"Undisclosed","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PersonGen BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"PersonGen BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Edinburgh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Edinburgh \/ Cyclacel Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Edinburgh \/ Cyclacel Pharmaceuticals"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Arthritis Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sodium Butyrate","moa":"Cholinesterase; Histone deacetylase 1; (S)-2-haloacid dehalogenase; 2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase","graph1":"Immunology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Arthritis Foundation","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Arthritis Foundation"},{"orgOrder":0,"company":"Hawthorne Effect Inc.","sponsor":"HLNatural, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hawthorne Effect Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hawthorne Effect Inc. \/ HLNatural, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Hawthorne Effect Inc. \/ HLNatural, Inc."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Amino Acid","year":"2011","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Immunology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Jiangxi Provincial People's Hospital","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Jiangxi Provincial People's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangxi Provincial People's Hospital \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Jiangxi Provincial People's Hospital \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Immunology","graph2":"Undisclosed","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Hofseth BioCare","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Partnership","leadProduct":"DHA","moa":"||DHA level","graph1":"Immunology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Catalent Pharma Solutions \/ Hofseth BioCare","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ Hofseth BioCare"},{"orgOrder":0,"company":"Tufts University","sponsor":"Prevention Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tufts University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tufts University \/ Prevention Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Tufts University \/ Prevention Pharmaceuticals"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"The Arthritis Society, Canada | University of Calgary | The Hospital for Sick Children | McGill University Health Centre Research Institute | London Health Sciences Centre | University of Manitoba | Alberta Children's Hospital | McMaster University | McMa","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ The Arthritis Society, Canada | University of Calgary | The Hospital for Sick Children | McGill University Health Centre Research Institute | London Health Sciences Centre | University of Manitoba | Alberta Children's Hospital | McMaster University | McMa","highestDevelopmentStatusID":"1","companyTruncated":"University of British Columbia \/ The Arthritis Society, Canada | University of Calgary | The Hospital for Sick Children | McGill University Health Centre Research Institute | London Health Sciences Centre | University of Manitoba | Alberta Children's Hospital | McMaster University | McMa"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Shanghai Zhongshan Hospital | Affiliated Hospital of Jilin University, Changchun,China | Second Affiliated Hospital, Nanchang University | The First Affiliated Hospital of Anhui Medical University | Beijing Shijitan Hospital, Capital Medical University | ","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Leflunomide","moa":"Dihydroorotate dehydrogenase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese SLE Treatment And Research Group \/ Shanghai Zhongshan Hospital | Affiliated Hospital of Jilin University, Changchun,China | Second Affiliated Hospital, Nanchang University | The First Affiliated Hospital of Anhui Medical University | Beijing Shijitan Hospital, Capital Medical University | ","highestDevelopmentStatusID":"1","companyTruncated":"Chinese SLE Treatment And Research Group \/ Shanghai Zhongshan Hospital | Affiliated Hospital of Jilin University, Changchun,China | Second Affiliated Hospital, Nanchang University | The First Affiliated Hospital of Anhui Medical University | Beijing Shijitan Hospital, Capital Medical University | "},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Azathioprine","moa":"DNA | Amidophosphoribosyltransferase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nantes University Hospital \/ Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","highestDevelopmentStatusID":"1","companyTruncated":"Nantes University Hospital \/ Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ambrisentan","moa":"Endothelin receptor, ET-A\/ET-B","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Pennsylvania \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"University of Pennsylvania \/ Gilead Sciences"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Undisclosed","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Northwestern University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of British Columbia \/ Astellas Pharma"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Magnesium","moa":"GABA-B receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Ghent \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital Ghent \/ Astellas Pharma"},{"orgOrder":0,"company":"Beijing Tongren Hospital","sponsor":"Beijing Institute of Otolaryngology | Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Beijing Tongren Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beijing Tongren Hospital \/ Beijing Institute of Otolaryngology | Johnson & Johnson","highestDevelopmentStatusID":"1","companyTruncated":"Beijing Tongren Hospital \/ Beijing Institute of Otolaryngology | Johnson & Johnson"},{"orgOrder":0,"company":"National University of Malaysia","sponsor":"HOE Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"MALAYSIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"National University of Malaysia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"National University of Malaysia \/ HOE Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"National University of Malaysia \/ HOE Pharmaceuticals"},{"orgOrder":0,"company":"Creighton University","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Creighton University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Creighton University \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"Creighton University \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Rochester \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"1","companyTruncated":"University of Rochester \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Shandong Qilu Stem Cells Engineering Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Shandong Qilu Stem Cells Engineering Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong Qilu Stem Cells Engineering Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shandong Qilu Stem Cells Engineering Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Taichung Veterans General Hospital","sponsor":"TSH Biopharm Corporation Limited","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"Glutamate [NMDA] receptor subunit epsilon 1 | Sigma opioid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Taichung Veterans General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taichung Veterans General Hospital \/ TSH Biopharm Corporation Limited","highestDevelopmentStatusID":"1","companyTruncated":"Taichung Veterans General Hospital \/ TSH Biopharm Corporation Limited"},{"orgOrder":0,"company":"Immunoflex Therapeutics Inc.","sponsor":"Dicentra Inc. | University of British Columbia","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase||Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Immunology","graph2":"Undisclosed","graph3":"Immunoflex Therapeutics Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunoflex Therapeutics Inc. \/ Dicentra Inc. | University of British Columbia","highestDevelopmentStatusID":"1","companyTruncated":"Immunoflex Therapeutics Inc. \/ Dicentra Inc. | University of British Columbia"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"Microbio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"MS-20","moa":"Gut microbiome","graph1":"Immunology","graph2":"Undisclosed","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"National Taiwan University Hospital \/ Microbio","highestDevelopmentStatusID":"1","companyTruncated":"National Taiwan University Hospital \/ Microbio"},{"orgOrder":0,"company":"Nanhua University","sponsor":"Buddhist Tzu Chi General Hospital | Solano Semiconductor Technology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nanhua University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanhua University \/ Buddhist Tzu Chi General Hospital | Solano Semiconductor Technology","highestDevelopmentStatusID":"1","companyTruncated":"Nanhua University \/ Buddhist Tzu Chi General Hospital | Solano Semiconductor Technology"},{"orgOrder":0,"company":"Nippon Kayaku","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Gusperimus","moa":"Hsp70","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nippon Kayaku","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nippon Kayaku \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nippon Kayaku \/ Undisclosed"},{"orgOrder":0,"company":"United Allergy Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Allergen Extract","moa":"IL-4 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Allergy Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Allergy Services \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Allergy Services \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"Probi AB","sponsor":"Lund University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Probi AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probi AB \/ Lund University","highestDevelopmentStatusID":"1","companyTruncated":"Probi AB \/ Lund University"},{"orgOrder":0,"company":"\u00d6rebro University","sponsor":"University of Hohenheim | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"\u00d6rebro University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"\u00d6rebro University \/ University of Hohenheim | Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"\u00d6rebro University \/ University of Hohenheim | Pfizer Inc"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2011","type":"Inapplicable","leadProduct":"Trichuris Suis Ova","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mycophenolic Acid","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"University of Wisconsin, Madison \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Takeda Pharmaceutical | Mauna Kea Technologies | INSERM","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nantes University Hospital \/ Takeda Pharmaceutical | Mauna Kea Technologies | INSERM","highestDevelopmentStatusID":"1","companyTruncated":"Nantes University Hospital \/ Takeda Pharmaceutical | Mauna Kea Technologies | INSERM"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"University of California, San Diego \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Tocilizumab","moa":"||Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Undisclosed","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Enzene Biosciences \/ Theramex","highestDevelopmentStatusID":"1","companyTruncated":"Enzene Biosciences \/ Theramex"},{"orgOrder":0,"company":"Omeros","sponsor":"Impatients N.V. trading as myTomorrows","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Immunology","graph2":"Undisclosed","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omeros \/ Impatients N.V. trading as myTomorrows","highestDevelopmentStatusID":"1","companyTruncated":"Omeros \/ Impatients N.V. trading as myTomorrows"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases | Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Immunology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases | Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases | Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Laboratorios Vi\u00f1as, S.A.","sponsor":"Hospital Vall d'Hebron | Laboratorio Echevarne","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laboratorios Vi\u00f1as, S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Vi\u00f1as, S.A. \/ Hospital Vall d'Hebron | Laboratorio Echevarne","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Vi\u00f1as, S.A. \/ Hospital Vall d'Hebron | Laboratorio Echevarne"},{"orgOrder":0,"company":"Laboratorios Vi\u00f1as, S.A.","sponsor":"Laboratorio Echevarne | Hospital Vall d'Hebron","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laboratorios Vi\u00f1as, S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Vi\u00f1as, S.A. \/ Laboratorio Echevarne | Hospital Vall d'Hebron","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Vi\u00f1as, S.A. \/ Laboratorio Echevarne | Hospital Vall d'Hebron"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Hope Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"HB-adMSC","moa":"Mesenchymal stem cells","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hope Biosciences \/ Hope Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Hope Biosciences \/ Hope Biosciences"},{"orgOrder":0,"company":"Hospital Universitari Vall d'Hebron Research Institute","sponsor":"Vitae Health Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hospital Universitari Vall d'Hebron Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitari Vall d'Hebron Research Institute \/ Vitae Health Innovation","highestDevelopmentStatusID":"1","companyTruncated":"Hospital Universitari Vall d'Hebron Research Institute \/ Vitae Health Innovation"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Sinocelltech Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ripertamab","moa":"monoclonal antibodies: tumors","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuhan Union Hospital \/ Sinocelltech Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Wuhan Union Hospital \/ Sinocelltech Ltd."},{"orgOrder":0,"company":"Hospital Universitari Vall d'Hebron Research Institute","sponsor":"Pharma Nord","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial; Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hospital Universitari Vall d'Hebron Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitari Vall d'Hebron Research Institute \/ Pharma Nord","highestDevelopmentStatusID":"1","companyTruncated":"Hospital Universitari Vall d'Hebron Research Institute \/ Pharma Nord"},{"orgOrder":0,"company":"University at Buffalo","sponsor":"Kaleida Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ezetimibe","moa":"Niemann-Pick C1-like protein 1","graph1":"Immunology","graph2":"Undisclosed","graph3":"University at Buffalo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University at Buffalo \/ Kaleida Health","highestDevelopmentStatusID":"1","companyTruncated":"University at Buffalo \/ Kaleida Health"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Aarhus \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"University of Aarhus \/ Novo Nordisk"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"National Institutes of Health | OnLume | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ National Institutes of Health | OnLume | National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"University of Wisconsin, Madison \/ National Institutes of Health | OnLume | National Cancer Institute"},{"orgOrder":0,"company":"Walter Reed National Military Medical Center","sponsor":"National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Immunology","graph2":"Undisclosed","graph3":"Walter Reed National Military Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walter Reed National Military Medical Center \/ National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"1","companyTruncated":"Walter Reed National Military Medical Center \/ National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"VSL Pharmaceuticals","sponsor":"Actial Farmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Undisclosed","graph3":"VSL Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VSL Pharmaceuticals \/ Actial Farmaceutica","highestDevelopmentStatusID":"1","companyTruncated":"VSL Pharmaceuticals \/ Actial Farmaceutica"},{"orgOrder":0,"company":"University of Memphis","sponsor":"Nordic Naturals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Memphis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Memphis \/ Nordic Naturals","highestDevelopmentStatusID":"1","companyTruncated":"University of Memphis \/ Nordic Naturals"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Carbohydrate","year":"2011","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"Radboud University Medical Center \/ ZonMw"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles","moa":"Progenitor cell","graph1":"Immunology","graph2":"Undisclosed","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Direct Biologics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Direct Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Laval University","sponsor":"Atrium Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laval University \/ Atrium Innovations","highestDevelopmentStatusID":"1","companyTruncated":"Laval University \/ Atrium Innovations"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Organic Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palmitoleic Acid","moa":"Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC)","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of North Carolina \/ Organic Technologies","highestDevelopmentStatusID":"1","companyTruncated":"University of North Carolina \/ Organic Technologies"},{"orgOrder":0,"company":"Curexsys Gmbh","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Exosome","moa":"PTEN","graph1":"Immunology","graph2":"Undisclosed","graph3":"Curexsys Gmbh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curexsys Gmbh \/ Evotec","highestDevelopmentStatusID":"1","companyTruncated":"Curexsys Gmbh \/ Evotec"},{"orgOrder":0,"company":"University Hospitals Cleveland Medical Center","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Alefacept","moa":"T-cell surface antigen CD2","graph1":"Immunology","graph2":"Undisclosed","graph3":"University Hospitals Cleveland Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospitals Cleveland Medical Center \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University Hospitals Cleveland Medical Center \/ Astellas Pharma"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Health Resources and Services Administration","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Immunology","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cleveland Clinic \/ Health Resources and Services Administration","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Health Resources and Services Administration"},{"orgOrder":0,"company":"Imperial College Healthcare NHS Trust","sponsor":"Merck & Co | Imperial College London","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Imperial College Healthcare NHS Trust","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College Healthcare NHS Trust \/ Merck & Co | Imperial College London","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College Healthcare NHS Trust \/ Merck & Co | Imperial College London"},{"orgOrder":0,"company":"Klinikum Westbrandenburg","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Klinikum Westbrandenburg","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Klinikum Westbrandenburg \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Klinikum Westbrandenburg \/ Undisclosed"},{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"Centocor","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oregon Health and Science University \/ Centocor","highestDevelopmentStatusID":"1","companyTruncated":"Oregon Health and Science University \/ Centocor"},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Abbott Laboratories | Swedish Foundation for Strategic Research | The Swedish Research Council","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Karolinska Institutet","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska Institutet \/ Abbott Laboratories | Swedish Foundation for Strategic Research | The Swedish Research Council","highestDevelopmentStatusID":"1","companyTruncated":"Karolinska Institutet \/ Abbott Laboratories | Swedish Foundation for Strategic Research | The Swedish Research Council"},{"orgOrder":0,"company":"Rabin Medical Center","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Rabin Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rabin Medical Center \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Rabin Medical Center \/ Abbott Laboratories"},{"orgOrder":0,"company":"University of Glasgow","sponsor":"Kappa Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Vitamin K2","moa":"Trypanosoma Cruzipain (Trypano CYSP)","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Glasgow","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Glasgow \/ Kappa Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"University of Glasgow \/ Kappa Bioscience"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Immunology","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"Aker BioMarine","sponsor":"Ampel BioSolutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"AKBM-3031","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Aker BioMarine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aker BioMarine \/ Ampel BioSolutions","highestDevelopmentStatusID":"1","companyTruncated":"Aker BioMarine \/ Ampel BioSolutions"},{"orgOrder":0,"company":"University of Western Ontario, Canada","sponsor":"Arthrex","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Acp","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Western Ontario, Canada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Western Ontario, Canada \/ Arthrex","highestDevelopmentStatusID":"1","companyTruncated":"University of Western Ontario, Canada \/ Arthrex"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Alfamino Junior","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Bispebjerg Hospital","sponsor":"ALK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Alk Alutard","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bispebjerg Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bispebjerg Hospital \/ ALK","highestDevelopmentStatusID":"1","companyTruncated":"Bispebjerg Hospital \/ ALK"},{"orgOrder":0,"company":"Greenyn Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Antrodia Cinnamomea Mycelia","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Greenyn Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Greenyn Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Greenyn Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Avobis Bio","sponsor":"Alimentiv","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"AVB-114","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Avobis Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avobis Bio \/ Alimentiv","highestDevelopmentStatusID":"1","companyTruncated":"Avobis Bio \/ Alimentiv"},{"orgOrder":0,"company":"Danisco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Bacterium Bifidobacterium Lactis","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Danisco \/ Undisclosed"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bif-038","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Undisclosed"},{"orgOrder":0,"company":"Hvidovre University Hospital","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bif195","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hvidovre University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hvidovre University Hospital \/ Chr. Hansen","highestDevelopmentStatusID":"1","companyTruncated":"Hvidovre University Hospital \/ Chr. Hansen"},{"orgOrder":0,"company":"The Center for Applied Health Sciences, LLC","sponsor":"Brightseed, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Piperine","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"The Center for Applied Health Sciences, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Center for Applied Health Sciences, LLC \/ Brightseed, Inc","highestDevelopmentStatusID":"1","companyTruncated":"The Center for Applied Health Sciences, LLC \/ Brightseed, Inc"},{"orgOrder":0,"company":"Bioray Laboratories","sponsor":"Shanghai Changzheng Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BRL-301","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bioray Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioray Laboratories \/ Shanghai Changzheng Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Bioray Laboratories \/ Shanghai Changzheng Hospital"},{"orgOrder":0,"company":"Bioray Laboratories","sponsor":"First Affiliated Hospital of Zhejiang University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BRL-301","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bioray Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioray Laboratories \/ First Affiliated Hospital of Zhejiang University","highestDevelopmentStatusID":"1","companyTruncated":"Bioray Laboratories \/ First Affiliated Hospital of Zhejiang University"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Arla Food for Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Casein","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Arla Food for Health","highestDevelopmentStatusID":"1","companyTruncated":"University of Aarhus \/ Arla Food for Health"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Arla Foods","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Casein Glycomacropeptide","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"University of Aarhus \/ Arla Foods","highestDevelopmentStatusID":"1","companyTruncated":"University of Aarhus \/ Arla Foods"},{"orgOrder":0,"company":"Hong Kong Sanatorium & Hospital","sponsor":"Chinese University of Hong Kong","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Chinese Herbal Formula - X","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hong Kong Sanatorium & Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hong Kong Sanatorium & Hospital \/ Chinese University of Hong Kong","highestDevelopmentStatusID":"1","companyTruncated":"Hong Kong Sanatorium & Hospital \/ Chinese University of Hong Kong"},{"orgOrder":0,"company":"Florida State University","sponsor":"Compound Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Corebiome","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Florida State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Florida State University \/ Compound Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Florida State University \/ Compound Solutions"},{"orgOrder":0,"company":"IPSC AG","sponsor":"Medical University of Graz | Sciotec Diagnostic Technologies GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"DAOSiN","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"IPSC AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IPSC AG \/ Medical University of Graz | Sciotec Diagnostic Technologies GmbH","highestDevelopmentStatusID":"1","companyTruncated":"IPSC AG \/ Medical University of Graz | Sciotec Diagnostic Technologies GmbH"},{"orgOrder":0,"company":"AB Biotek","sponsor":"Hospital Clinic of Barcelona","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Diamino Oxidase","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"AB Biotek","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Biotek \/ Hospital Clinic of Barcelona","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotek \/ Hospital Clinic of Barcelona"},{"orgOrder":0,"company":"Sahlgrenska University Hospital","sponsor":"Calmino group AB","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Dietary Fiber","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sahlgrenska University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sahlgrenska University Hospital \/ Calmino group AB","highestDevelopmentStatusID":"1","companyTruncated":"Sahlgrenska University Hospital \/ Calmino group AB"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"EHF","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Ensure Enlive","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Johns Hopkins University \/ Abbott Laboratories"},{"orgOrder":0,"company":"Enovate Biolife","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"E-RH-06","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Enovate Biolife","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enovate Biolife \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Enovate Biolife \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Extensively Hydrolyzed Rice Protein Formula","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bio Nature Health","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Eye Empower","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bio Nature Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bio Nature Health \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Bio Nature Health \/ Citruslabs"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"St. Joseph's Health Care London","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ St. Joseph's Health Care London","highestDevelopmentStatusID":"1","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ St. Joseph's Health Care London"},{"orgOrder":0,"company":"Appalachian State University","sponsor":"Reoxcyn Discoveries Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Flavonoids","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Appalachian State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appalachian State University \/ Reoxcyn Discoveries Group","highestDevelopmentStatusID":"1","companyTruncated":"Appalachian State University \/ Reoxcyn Discoveries Group"},{"orgOrder":0,"company":"Hospital Universitari Vall d'Hebron Research Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"FOS","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hospital Universitari Vall d'Hebron Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitari Vall d'Hebron Research Institute \/ AbbVie Inc","highestDevelopmentStatusID":"1","companyTruncated":"Hospital Universitari Vall d'Hebron Research Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"GLSMED Learning Health S.A.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"PORTUGAL","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Glycan","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"GLSMED Learning Health S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GLSMED Learning Health S.A. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"GLSMED Learning Health S.A. \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneBiotech Medical Sweden AB","sponsor":"Karolinska Institutet","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Gutmagnific\u2122 H: Gutmagnific","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"ImmuneBiotech Medical Sweden AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneBiotech Medical Sweden AB \/ Karolinska Institutet","highestDevelopmentStatusID":"1","companyTruncated":"ImmuneBiotech Medical Sweden AB \/ Karolinska Institutet"},{"orgOrder":0,"company":"Shenzhen MagicRNA Biotechnology Co., Ltd","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HN2301","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Shenzhen MagicRNA Biotechnology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen MagicRNA Biotechnology Co., Ltd \/ The First Affiliated Hospital of University of Science and Technology of China","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen MagicRNA Biotechnology Co., Ltd \/ The First Affiliated Hospital of University of Science and Technology of China"},{"orgOrder":0,"company":"Shenzhen MagicRNA Biotechnology Co., Ltd","sponsor":"Songjiang Hospital, Shanghai Jiao Tong University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HN2301","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Shenzhen MagicRNA Biotechnology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen MagicRNA Biotechnology Co., Ltd \/ Songjiang Hospital, Shanghai Jiao Tong University","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen MagicRNA Biotechnology Co., Ltd \/ Songjiang Hospital, Shanghai Jiao Tong University"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Ecarf Institute GmbH | Bencard Allergie GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"holoBLG","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Ecarf Institute GmbH | Bencard Allergie GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Allergy Therapeutics \/ Ecarf Institute GmbH | Bencard Allergie GmbH"},{"orgOrder":0,"company":"Big Bold Health, PBC","sponsor":"TruDiagnostic","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"HTB Rejuvenate","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Big Bold Health, PBC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Big Bold Health, PBC \/ TruDiagnostic","highestDevelopmentStatusID":"1","companyTruncated":"Big Bold Health, PBC \/ TruDiagnostic"},{"orgOrder":0,"company":"Newcastle University","sponsor":"Aelius Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Huel","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Newcastle University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Newcastle University \/ Aelius Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Newcastle University \/ Aelius Biotech"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Human Amniotic Epithelial Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University People's Hospital \/ Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China","highestDevelopmentStatusID":"1","companyTruncated":"Peking University People's Hospital \/ Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Hydrolyzed Egg","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Hydrolyzed Protein","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kate Farms Inc","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"IBD-AID Diet","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kate Farms Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kate Farms Inc \/ University of Minnesota","highestDevelopmentStatusID":"1","companyTruncated":"Kate Farms Inc \/ University of Minnesota"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Grifols International","highestDevelopmentStatusID":"1","companyTruncated":"University of Alabama at Birmingham \/ Grifols International"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"University Health Network, Toronto \/ CSL Behring"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2021","type":"Series B Financing","leadProduct":"Imotope","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Imcyse","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Imcyse \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Imcyse \/ Pfizer Inc"},{"orgOrder":0,"company":"Edifice Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Iron Bisglycinate Manganese Chloride","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Edifice Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edifice Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Edifice Health \/ Undisclosed"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"IVIG","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ CSL Behring"},{"orgOrder":0,"company":"Jantar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JT-1","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Jantar","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jantar \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Jantar \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Genocury Biotech","sponsor":"LiangZou","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"JY231","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Shenzhen Genocury Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen Genocury Biotech \/ LiangZou","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen Genocury Biotech \/ LiangZou"},{"orgOrder":0,"company":"KeraNetics, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Keratin","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"KeraNetics, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Cream","sponsorNew":"KeraNetics, LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"KeraNetics, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"L. Paracasei Fermented Milk","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"TNO","sponsor":"VSL Pharmaceuticals | NIZO Food Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Lactic Acid Bacteria","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"TNO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TNO \/ VSL Pharmaceuticals | NIZO Food Research","highestDevelopmentStatusID":"1","companyTruncated":"TNO \/ VSL Pharmaceuticals | NIZO Food Research"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Lactobacillus Fermentum CECT5716","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kerry Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Undisclosed"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Lactobacillus Fermentum CECT5716","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kerry Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Undisclosed"},{"orgOrder":0,"company":"Universidad Complutense de Madrid","sponsor":"National Research Council, Spain | University of Valencia | Danone Global Research & Innovation Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Lactobacillus Salivarius PS2","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Universidad Complutense de Madrid","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Universidad Complutense de Madrid \/ National Research Council, Spain | University of Valencia | Danone Global Research & Innovation Center","highestDevelopmentStatusID":"1","companyTruncated":"Universidad Complutense de Madrid \/ National Research Council, Spain | University of Valencia | Danone Global Research & Innovation Center"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"SYNBIO TECH INC. Kaohsiung Taiwan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"LDL557-HK","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ SYNBIO TECH INC. Kaohsiung Taiwan","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ SYNBIO TECH INC. Kaohsiung Taiwan"},{"orgOrder":0,"company":"Appalachian State University","sponsor":"LycoRed Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Lycored Product","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Appalachian State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appalachian State University \/ LycoRed Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Appalachian State University \/ LycoRed Ltd."},{"orgOrder":0,"company":"Supplement Formulators, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Marine Lipid Oil Concentrate","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Supplement Formulators, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Supplement Formulators, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Supplement Formulators, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Supplement Formulators, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Marine Lipid Oil Concentrate","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Supplement Formulators, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Supplement Formulators, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Supplement Formulators, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Undisclosed","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Avacta Group","highestDevelopmentStatusID":"1","companyTruncated":"Daewoong Pharmaceutical \/ Avacta Group"},{"orgOrder":0,"company":"Universidad de la Sabana","sponsor":"Fundaci\u00f3n Neumologica Colombiana | Innocell SAS | Stem Medicina Regenerativa","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"COLOMBIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Undisclosed","graph3":"Universidad de la Sabana","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad de la Sabana \/ Fundaci\u00f3n Neumologica Colombiana | Innocell SAS | Stem Medicina Regenerativa","highestDevelopmentStatusID":"1","companyTruncated":"Universidad de la Sabana \/ Fundaci\u00f3n Neumologica Colombiana | Innocell SAS | Stem Medicina Regenerativa"},{"orgOrder":0,"company":"University of Exeter","sponsor":"Advanced Growers Limited | Ecog Pro Limited","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Micro-Vegetable Blend","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Exeter","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Exeter \/ Advanced Growers Limited | Ecog Pro Limited","highestDevelopmentStatusID":"1","companyTruncated":"University of Exeter \/ Advanced Growers Limited | Ecog Pro Limited"},{"orgOrder":0,"company":"Hasanuddin University","sponsor":"Arla Foods","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDONESIA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hasanuddin University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hasanuddin University \/ Arla Foods","highestDevelopmentStatusID":"1","companyTruncated":"Hasanuddin University \/ Arla Foods"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"NIZO Food Research","sponsor":"FrieslandCampina | Wageningen University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Milk Protein","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"NIZO Food Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIZO Food Research \/ FrieslandCampina | Wageningen University","highestDevelopmentStatusID":"1","companyTruncated":"NIZO Food Research \/ FrieslandCampina | Wageningen University"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"The Alfred | Melbourne Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Moderate Oligosaccharide Group","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ The Alfred | Melbourne Health","highestDevelopmentStatusID":"1","companyTruncated":"University of British Columbia \/ The Alfred | Melbourne Health"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Monosaccharides","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Egil Johnson","sponsor":"ImmunoPharma AS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Mushroom Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Egil Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egil Johnson \/ ImmunoPharma AS","highestDevelopmentStatusID":"1","companyTruncated":"Egil Johnson \/ ImmunoPharma AS"},{"orgOrder":0,"company":"Fraunhofer-Institute of Toxicology and Experimental Medicine","sponsor":"MetP Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Nascum Plus","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Fraunhofer-Institute of Toxicology and Experimental Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fraunhofer-Institute of Toxicology and Experimental Medicine \/ MetP Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Fraunhofer-Institute of Toxicology and Experimental Medicine \/ MetP Pharma"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"New Extensively Hydrolysed Formula","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Base Therapeutics","sponsor":"The First Affiliated Hospital of Anhui Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NK510","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Base Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Base Therapeutics \/ The First Affiliated Hospital of Anhui Medical University","highestDevelopmentStatusID":"1","companyTruncated":"Base Therapeutics \/ The First Affiliated Hospital of Anhui Medical University"},{"orgOrder":0,"company":"Georgetown University","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Normal Human Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Georgetown University \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"Georgetown University \/ CSL Behring"},{"orgOrder":0,"company":"Baptist Memorial Health Care Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Baptist Memorial Health Care Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baptist Memorial Health Care Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Baptist Memorial Health Care Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Oshadi Drug Administration","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SRI LANKA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Oshadi D","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Oshadi Drug Administration","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oshadi Drug Administration \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oshadi Drug Administration \/ Undisclosed"},{"orgOrder":0,"company":"Instituto de Investigacion Sanitaria La Fe","sponsor":"Adventia Pharma | Biopolis S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Peptidic","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Instituto de Investigacion Sanitaria La Fe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto de Investigacion Sanitaria La Fe \/ Adventia Pharma | Biopolis S.L.","highestDevelopmentStatusID":"1","companyTruncated":"Instituto de Investigacion Sanitaria La Fe \/ Adventia Pharma | Biopolis S.L."},{"orgOrder":0,"company":"University Hospital, Montpellier","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Pneumococcal Polysaccharide Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University Hospital, Montpellier","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Montpellier \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital, Montpellier \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Wageningen University","sponsor":"Winclove Probiotics B.V. | China Scholarship Council","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Prebiotic","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wageningen University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wageningen University \/ Winclove Probiotics B.V. | China Scholarship Council","highestDevelopmentStatusID":"1","companyTruncated":"Wageningen University \/ Winclove Probiotics B.V. | China Scholarship Council"},{"orgOrder":0,"company":"Stanford University","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Prebiotic","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Stanford University \/ Abbott Laboratories"},{"orgOrder":0,"company":"Szeged University","sponsor":"Research Centre for Natural Sciences | University of Debrecen Dept. of Rheumatology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HUNGARY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Pyrophosphate","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Szeged University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Szeged University \/ Research Centre for Natural Sciences | University of Debrecen Dept. of Rheumatology","highestDevelopmentStatusID":"1","companyTruncated":"Szeged University \/ Research Centre for Natural Sciences | University of Debrecen Dept. of Rheumatology"},{"orgOrder":0,"company":"Qualia Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Qualia Senolytic","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Qualia Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualia Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Qualia Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Statitec","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Rice","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Statitec","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Statitec"},{"orgOrder":0,"company":"Laval University","sponsor":"Ministry of Agriculture, Fisheries and Food, Quebec | Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Seal Oil","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Laval University \/ Ministry of Agriculture, Fisheries and Food, Quebec | Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Laval University \/ Ministry of Agriculture, Fisheries and Food, Quebec | Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc."},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Short Chain Fatty Acid","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Affyxell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Stefin A","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ Affyxell Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Avacta Group \/ Affyxell Therapeutics"},{"orgOrder":0,"company":"Beijing GoBroad Hospital","sponsor":"Starna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"STR-P004","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Beijing GoBroad Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing GoBroad Hospital \/ Starna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Beijing GoBroad Hospital \/ Starna Therapeutics"},{"orgOrder":0,"company":"University of Alberta","sponsor":"Canadian Institutes of Health Research | Crohn's and Colitis Canada | Beneo","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Synergy1","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alberta \/ Canadian Institutes of Health Research | Crohn's and Colitis Canada | Beneo","highestDevelopmentStatusID":"1","companyTruncated":"University of Alberta \/ Canadian Institutes of Health Research | Crohn's and Colitis Canada | Beneo"},{"orgOrder":0,"company":"Standard Process Inc.","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TPG1","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Standard Process Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Standard Process Inc. \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Standard Process Inc. \/ Nutrasource"},{"orgOrder":0,"company":"Tract Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"TRK-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tract Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tract Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tract Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Charles University, Czech Republic","sponsor":"Iscare i.v.f., Czech Republic | CD Investments srl | University Of Perugia | University of Roma La Sapienza","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CZECH REPUBLIC","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"VSL#3","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Charles University, Czech Republic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles University, Czech Republic \/ Iscare i.v.f., Czech Republic | CD Investments srl | University Of Perugia | University of Roma La Sapienza","highestDevelopmentStatusID":"1","companyTruncated":"Charles University, Czech Republic \/ Iscare i.v.f., Czech Republic | CD Investments srl | University Of Perugia | University of Roma La Sapienza"},{"orgOrder":0,"company":"Exosomm Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Whey Protein Milk-Derived Exosome","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Exosomm Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exosomm Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Exosomm Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"University of South Florida","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Zoster Vaccine, Live","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of South Florida","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of South Florida \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"University of South Florida \/ Merck & Co"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"QATAR","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"McMaster University","sponsor":"Canadian Association of Gastroenterology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McMaster University \/ Canadian Association of Gastroenterology","highestDevelopmentStatusID":"1","companyTruncated":"McMaster University \/ Canadian Association of Gastroenterology"},{"orgOrder":0,"company":"Innowage Limited","sponsor":"Mettle Networks","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innowage Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innowage Limited \/ Mettle Networks","highestDevelopmentStatusID":"1","companyTruncated":"Innowage Limited \/ Mettle Networks"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pharmaceutical \/ Argenx"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyowa Kirin","amount2":0.44,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.44,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Kirin \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yangtze River Pharmaceutical Group \/ Alvotech","highestDevelopmentStatusID":"1","companyTruncated":"Yangtze River Pharmaceutical Group \/ Alvotech"},{"orgOrder":0,"company":"Universit\u00e9 Libre de Bruxelles","sponsor":"DESCARTES Working Group On Transplantation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Universit\u00e9 Libre de Bruxelles","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e9 Libre de Bruxelles \/ DESCARTES Working Group On Transplantation","highestDevelopmentStatusID":"1","companyTruncated":"Universit\u00e9 Libre de Bruxelles \/ DESCARTES Working Group On Transplantation"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"LFB Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Lille \/ LFB Group","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital, Lille \/ LFB Group"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ Undisclosed"},{"orgOrder":0,"company":"AB Biotics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"AB Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Biotics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotics \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Geneva","sponsor":"Biomerieux","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University Hospital, Geneva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Geneva \/ Biomerieux","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital, Geneva \/ Biomerieux"},{"orgOrder":0,"company":"Galvani Bioelectronics","sponsor":"NAMSA | Q2 Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Galvani Bioelectronics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galvani Bioelectronics \/ NAMSA | Q2 Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Galvani Bioelectronics \/ NAMSA | Q2 Solutions"},{"orgOrder":0,"company":"Genmab","sponsor":"Tavotek Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Tavotek Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Genmab \/ Tavotek Biotherapeutics"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"OMass Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"OMass Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"1","companyTruncated":"OMass Therapeutics \/ Syncona Limited"},{"orgOrder":0,"company":"Camallergy","sponsor":"OnDosis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Camallergy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Camallergy \/ OnDosis","highestDevelopmentStatusID":"1","companyTruncated":"Camallergy \/ OnDosis"},{"orgOrder":0,"company":"Sanofi","sponsor":"Fidia Farmaceutici Spa","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Divestment","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Fidia Farmaceutici Spa","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ Fidia Farmaceutici Spa"},{"orgOrder":0,"company":"Mogrify","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Mogrify","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mogrify \/ Sangamo Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mogrify \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inside Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inside Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"OSE Immunotherapeutics SA \/ Inside Therapeutics"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Slb Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Slb Pharma","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Slb Pharma"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"EGYPT","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Minapharm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minapharm Pharmaceuticals \/ Bioventure Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"Minapharm Pharmaceuticals \/ Bioventure Healthcare"},{"orgOrder":0,"company":"Prollergy dba Ready Set Food","sponsor":"ObvioHealth","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Prollergy dba Ready Set Food","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prollergy dba Ready Set Food \/ ObvioHealth","highestDevelopmentStatusID":"1","companyTruncated":"Prollergy dba Ready Set Food \/ ObvioHealth"},{"orgOrder":0,"company":"Bend Beauty Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bend Beauty Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bend Beauty Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bend Beauty Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Steritas","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Steritas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Steritas \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Steritas \/ Argenx"},{"orgOrder":0,"company":"Utah State University","sponsor":"USANA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Utah State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Utah State University \/ USANA Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Utah State University \/ USANA Health Sciences"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nuvig Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Inhalation","sponsorNew":"Nuvig Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Nuvig Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"GRO Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"GRO Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"GRO Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"1","companyTruncated":"GRO Biosciences \/ Leaps by Bayer"},{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ SAB Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ SAB Biotherapeutics"},{"orgOrder":0,"company":"Forward Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Forward Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Forward Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"1","companyTruncated":"Forward Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sonoma Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Sonoma Biotherapeutics \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Orbital Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam Therapeutics \/ Orbital Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Beam Therapeutics \/ Orbital Therapeutics"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyverna Therapeutics","amount2":0.58999999999999997,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.58999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Kyverna Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyverna Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Vida Ventures LLC","highestDevelopmentStatusID":"1","companyTruncated":"Kyverna Therapeutics \/ Vida Ventures LLC"},{"orgOrder":0,"company":"Peter Korsten","sponsor":"DiaMed GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Peter Korsten","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peter Korsten \/ DiaMed GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Peter Korsten \/ DiaMed GmbH"},{"orgOrder":0,"company":"Vitae Health Innovation","sponsor":"Hospital Vall d'Hebron","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Vitae Health Innovation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitae Health Innovation \/ Hospital Vall d'Hebron","highestDevelopmentStatusID":"1","companyTruncated":"Vitae Health Innovation \/ Hospital Vall d'Hebron"},{"orgOrder":0,"company":"The Affiliated Hospital of Xuzhou Medical University","sponsor":"Shanghai Xiniao Biotech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"UCAR-T Cell","moa":"CD19","graph1":"Immunology","graph2":"Undisclosed","graph3":"The Affiliated Hospital of Xuzhou Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Affiliated Hospital of Xuzhou Medical University \/ Shanghai Xiniao Biotech Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"The Affiliated Hospital of Xuzhou Medical University \/ Shanghai Xiniao Biotech Co., Ltd."},{"orgOrder":0,"company":"SecondWave Systems","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"SecondWave Systems","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SecondWave Systems \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SecondWave Systems \/ Undisclosed"},{"orgOrder":0,"company":"ShenZhen Cell Valley","sponsor":"First Affiliated Hospital of China Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"ShenZhen Cell Valley","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ShenZhen Cell Valley \/ First Affiliated Hospital of China Medical University","highestDevelopmentStatusID":"1","companyTruncated":"ShenZhen Cell Valley \/ First Affiliated Hospital of China Medical University"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hikma Pharmaceuticals \/ Celltrion","highestDevelopmentStatusID":"1","companyTruncated":"Hikma Pharmaceuticals \/ Celltrion"},{"orgOrder":0,"company":"Kamada","sponsor":"Impatients N.V. trading as myTomorrows","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Alpha1-Proteinase Inhibitor (Human)","moa":"Leukocyte elastase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Impatients N.V. trading as myTomorrows","highestDevelopmentStatusID":"1","companyTruncated":"Kamada \/ Impatients N.V. trading as myTomorrows"},{"orgOrder":0,"company":"PROMETHEUS LABS","sponsor":"Shradha Agarwal","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"PROMETHEUS LABS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PROMETHEUS LABS \/ Shradha Agarwal","highestDevelopmentStatusID":"1","companyTruncated":"PROMETHEUS LABS \/ Shradha Agarwal"}]

    Find Novel Immunology Drugs in Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Fidia Farmaceutici Spa

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Sanofi Continues Streamlining of Established Products with Sale of Anti-Inflammatory Drugs to Fidia Farmaceuti...

                            Details : The agreement covers the registrations, trademarks, and related commercial rights of seven products, including four corticosteroids and one non-steroidal anti-inflammatory drug, across Europe and Emerging Markets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 23, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Fidia Farmaceutici Spa

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbbVie Inc

                            U.S.A
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upadacitinib

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access to Upadacitinib

                            Details : Upadacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 12, 2019

                            Lead Product(s) : Upadacitinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbbVie Inc

                            U.S.A
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risankizumab

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access to Risankizumab

                            Details : Risankizumab is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 16, 2019

                            Lead Product(s) : Risankizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AbbVie Inc

                            U.S.A
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : waqqas.afif

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TDM Guided Early Optimization of ADAL in Crohn's Disease

                            Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 24, 2017

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : waqqas.afif

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hikma Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hikma Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA

                            Details : Through the licensing deal, an undisclosed product for allergic diseases will be developed, addressing key focus areas in this therapeutic area.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 06, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ShenZhen Cell Valley

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ShenZhen Cell Valley

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD19 CAR-T Cell

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : First Affiliated Hospital of China Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CAR-T in Subjects With Relapsed/Refractory Autoimmune Disease

                            Details : CD19 CAR-T Cell is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Autoimmune Diseases.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 26, 2025

                            Lead Product(s) : CD19 CAR-T Cell

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : First Affiliated Hospital of China Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SecondWave Systems

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SecondWave Systems

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]

                            Details : This drug candidate is currently being evaluated in Undisclosed clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 09, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            The Affiliated Hospital of Xuzhou Medical University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            The Affiliated Hospital of Xuzhou Medical University

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UCAR-T Cell

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Shanghai Xiniao Biotech Co., Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

                            Details : UCAR-T Cell is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Lupus Erythematosus, Systemic.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 04, 2025

                            Lead Product(s) : UCAR-T Cell

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Shanghai Xiniao Biotech Co., Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Beijing GoBroad Hospital

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Beijing GoBroad Hospital

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STR-P004

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Starna Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            STR-P004 Safety Study In Relapsed Or Refractory Autoimmune Diseases

                            Details : STR-P004 is a Cell and Gene therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Autoimmune Diseases.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 27, 2025

                            Lead Product(s) : STR-P004

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Starna Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kate Farms Inc

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Kate Farms Inc

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IBD-AID Diet

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : University of Minnesota

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Partial-enteral Nutrition Protocol for Crohn's Disease

                            Details : IBD-AID Diet is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            August 08, 2025

                            Lead Product(s) : IBD-AID Diet

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : University of Minnesota

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth